Brief: Novavax Says Co, SK Bioscience File Post Approval Change Application In South Korea For Nuvaxovid Covid Vaccine As Booster In Adults Aged 18 & Older-Statement
10/10/2022 13:48
Oct 10 (Reuters) -
* NOVAVAX, SK BIOSCIENCE FILE POST APPROVAL CHANGE
APPLICATION IN
SOUTH KOREA FOR NUVAXOVID COVID VACCINE AS BOOSTER IN ADULTS
AGED 18 & OLDER-STATEMENT
Source text: https://bit.ly/3yt9zPa
((Reuters.briefs@thomsonreuters.com;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine